Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Although cyclodextrin building blocks are biological products generated by microbial enzymes, decades of commercial use in foods and solvents matured their extraction. This industrial scale allows modern therapeutics to source ultrapure starting materials cheaply at scale without investing in complex upstream fermentation development.

Related Insights

Cyclodextrin therapeutics fail to absorb into systemic circulation through the gastrointestinal tract regardless of modifications made to their structure. Consequently, developers must design programs from the outset around subcutaneous injections, self-administered pens, or osmotic pumps rather than attempting oral delivery formulations.

The primary challenge in finding drugs from nature has shifted. Initially, it was culturing microbes, then avoiding rediscovery of known molecules. Today, with advanced screening generating vast data, the bottleneck is prioritizing the most promising chemical hits for drug development.

In biomanufacturing, purifying a product is a major cost. Using an organism that secretes the product directly into the media eliminates the need for cell lysis and reduces endotoxin concerns. This simplification of downstream processing can cut total production costs by 25-33%, a significant competitive advantage.

Contract manufacturing organizations often assume cyclodextrin dimerization behaves like conventional small-molecule synthesis, proposing process modifications that fail in practice. Specialized carbohydrate chemistry behaves unpredictably, requiring therapeutic sponsors to temper vendor confidence and actively guide external manufacturing teams.

Partially substituted cyclodextrins generate semi-random, stochastic isomeric mixtures across 21 hydroxyl reaction sites. Instead of purifying a single isomer, developers establish lot-to-lot comparability for regulators by tracking identical 2D NMR and mass spectrometry distribution patterns alongside in vitro safety and activity assays.

Instead of rushing to the clinic, MRM Health deliberately slowed down for five years to develop its CORAL platform. This end-to-end platform solves strain selection, single-process manufacturing, and delivery upfront, preventing the CMC (Chemistry, Manufacturing, and Controls) issues that plagued earlier microbiome companies.

Many companies are creating bio-based alternatives to petroleum products but lack a scalable, affordable feedstock supplier. The most significant opportunity lies in creating this foundational infrastructure—a 'biological equivalent to a standard oil'—to enable the entire sustainable manufacturing ecosystem to compete on price and scale.

Cyclodextrin dimers sit between 2,000 and 3,000 Daltons, functioning like therapeutic antibodies by sequestering targets without metabolic transformation. Despite exceeding classical size boundaries, they are synthesized via stepwise chemistry and handled by FDA CDER under small molecule regulatory expectations.

Merck's biocatalysis platform starts with enzymes from nature and uses directed evolution—iterative lab-based mutation and selection—to create novel manufacturing tools. This process rapidly builds unnatural functions, enabling the scalable synthesis of complex drugs that would otherwise be impractical.

Early-stage biotechs often build companies purely around novel scientific concepts while neglecting manufacturability and patient access. Thinking through manufacturability from day one ensures that complex biologics can actually be produced affordably and delivered to patients, preventing bioprocessing bottlenecks when transitioning candidates toward clinical and commercial development.